e.g. mhealth
Search Results (1 to 5 of 5 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 3 JMIR Research Protocols
- 1 JMIR Formative Research
- 1 JMIR Medical Education
- 0 Journal of Medical Internet Research
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Human Factors
- 0 JMIR Medical Informatics
- 0 JMIR Public Health and Surveillance
- 0 JMIR mHealth and uHealth
- 0 JMIR Serious Games
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Cancer
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Dermatology
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIR Nursing
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey
Examples of schedule III medications include buprenorphine (Suboxone), testosterone, and ketamine. It is plausible that nonpsychiatry specialists, unlikely to prescribe buprenorphine or ketamine in their practices, may have based their response on other medications within schedule III, medications with which they are more familiar.
All addiction psychiatry or medicine specialists indicated a high level of comfort in prescribing schedule III medications.
JMIR Form Res 2025;9:e63251
Download Citation: END BibTex RIS
In the wake of the COVID-19 pandemic, a group of academic clinicians at the University of Oxford and psychiatry trainees in the United Kingdom recognized the need for a platform to share knowledge about ketamine and related compounds in psychiatry. Their ultimate goal was to connect researchers and clinical practitioners. This initiative led to the establishment of the Ketamine and Related Compounds International Journal Club (KIJC), subsequently referred to as the journal club.
JMIR Med Educ 2023;9:e46158
Download Citation: END BibTex RIS
Racemic ketamine and its enantiomer esketamine have been studied as novel alternatives for treatment-resistant depression (TRD) in major depressive disorder (MDD) and bipolar depression [1-3]. Studies with intravenous (IV) racemic ketamine have demonstrated rapid and potent reduction of depressive symptoms after the administration of a single subanesthetic dose (response rate=3.01, 95% CI 1.96-4.62; remission rate=3.70, 95% CI 2.28-6.01) [4-8].
JMIR Res Protoc 2022;11(5):e34711
Download Citation: END BibTex RIS
It has also been reported that the route of administration of ketamine can influence the clinical antidepressant effects of treatment owing to its extensive first-pass metabolism; specifically, the highest bioavailability of ketamine is achieved via intravenous infusion, while oral administration yields the lowest bioavailability [13].
JMIR Res Protoc 2022;11(1):e30163
Download Citation: END BibTex RIS
The objective of this study is to provide a greater reduction in symptoms with a combination treatment of ketamine and electronically delivered cognitive behavioral therapy (e-CBT) as compared with currently available therapeutic options for treatment-resistant patients.
Ketamine offers a promising research avenue for treating refractory PTSD.
JMIR Res Protoc 2021;10(7):e30334
Download Citation: END BibTex RIS